TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8062496

Group type: EXPERIMENTAL
Intervention: Chronomodulated schedule (oxaliplatin at 4 pm, 5-fluorouracil and folinic acid at 4 am)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Constant rate schedule
Number of subjects: 9
Study: 2526008

Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg intravenous bolus
Number of subjects: 28
Study: 5440545

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Gas and oxygen machine (50% oxygen and 50% nitrous oxide)
Number of subjects: 778
Study: 30540548

Group type: EXPERIMENTAL
Intervention: Alcohol consumption among student-athletes
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Protective behavioral strategies (PBS)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Within-group gender differences in alcohol use and PBS
Number of subjects: 670
Study: 31300507

Group type: EXPERIMENTAL
Intervention: Surgery at 6 months of age (Sommerlad technique)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Surgery at 12 months of age (Sommerlad technique)
Number of subjects: 600
Study: 27820725

Group type: EXPERIMENTAL
Intervention: Olympic-style weightlifting (OWL)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Motorized strength and power training (MSPT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Free weight strength and power training (FSPT)
Number of subjects: 39
Study: 24894344

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Continuous erythropoietin receptor activator (CERA)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Epoetin alfa or beta
Number of subjects: 327

Group type: COMPARATOR
Intervention: Darbepoetin
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: CERA
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 327
Study: 24240244

Group type: EXPERIMENTAL
Intervention: 13.5 mg levonorgestrel intrauterine contraceptive system
Number of subjects: 2884

Group type: EXPERIMENTAL
Intervention: 19.5 mg levonorgestrel intrauterine contraceptive system
Number of subjects: 2884
Study: 21620765

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients (N=20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls (N=18)
Number of subjects: 38
Study: 18081728

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 42
Study: 16506273

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Glibenclamide (5 mg/d)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Voglibose (0.6 mg/d)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nateglinide (270 mg/d)
Number of subjects: 68
Study: 12672168

Group type: EXPERIMENTAL
Intervention: Alcohol received (0.5 g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol received (0.5 g/kg) with expectancy of alcohol (2-3 standard drinks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No alcohol received (0.0 g/kg) and no expectancy
Number of subjects: 0
Study: 11196347

Group type: EXPERIMENTAL
Intervention: 360 mg/day of anapsos
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 720 mg/day of anapsos
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 9195694

Group type: EXPERIMENTAL
Intervention: Fenwal CS3000
Number of subjects: 29
Study: 8008366

Group type: EXPERIMENTAL
Intervention: Tisacid suspension (2.0 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tisacid tablet (2.0 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tisacid suspension (1.0 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tisacid tablet (1.0 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tisacid suspension (0.5 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tisacid tablet (0.5 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (after administration of tablet or suspension)
Number of subjects: 10
Study: 3051475

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (2 ml/cm incision) infiltrated into the fascia
Number of subjects: 415

Group type: COMPARATOR
Intervention: Closure without infiltration
Number of subjects: 415
Study: 31222586

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 70
Study: 28392340

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 36
Study: 26165173

Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Therapy (SMT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nontherapeutic Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 29
Study: 23332680

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 21168536

Group type: EXPERIMENTAL
Intervention: teriparatide 20 μg/day
Number of subjects: 207

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 207
Study: 18290864

Group type: EXPERIMENTAL
Intervention: Late hypoglycaemia (nadir of 2.2 mmol/l after 3.5 h of sleep)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Early hypoglycaemia (nadir of 2.2 mmol/l after 1 h of sleep)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition (no hypoglycaemia induced)
Number of subjects: 16
Study: 16817277

Group type: EXPERIMENTAL
Intervention: Danshen Jueming Granules
Number of subjects: 96

Group type: COMPARATOR
Intervention: Xuezhikang Capsules
Number of subjects: 96
Study: 14622630

Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 11152307

Group type: EXPERIMENTAL
Intervention: In-house IgG EIA
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Abbott AxSym IgG
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Captia Select Toxo-G
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Toxreagent 'Eiken'
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Toxolatex Fumouze
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sabin-Feldman dye test
Number of subjects: 177
Study: 9110115

Group type: EXPERIMENTAL
Intervention: Bosentan (300 mg, intravenous)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Bosentan (0.5 g bid, orally for 14 days)
Number of subjects: 2
Study: 1530434

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 5 micrograms of ISDN
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 15 micrograms of ISDN
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 60 micrograms of ISDN
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 240 micrograms of ISDN
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 1,000 micrograms of ISDN
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (only received ergometrine)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Doses greater than 240 micrograms of ISDN
Number of subjects: 16
Study: 4093207

Group type: EXPERIMENTAL
Intervention: MONOCLAIR (40 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: ISMO (40 mg)
Number of subjects: 8
Study: 31410465

Group type: EXPERIMENTAL
Intervention: low SCFPns (12 g SCFPns·steer‐1·d‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: medium SCFPns (15 g SCFPns·steer‐1·d‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: high SCFPns (18 g SCFPns·steer‐1·d‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: eXPC (7 g XPC·steer‐1·d‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ANT (330 mg monensin + 110 mg tylosin·steer‐1·d‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: control
Number of subjects: 90
Study: 30035583

Group type: EXPERIMENTAL
Intervention: Expand Your Horizon intervention (3 writing exercises focusing on body functionality)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 84
Study: 27381275

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/d
Number of subjects: 407

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg/d
Number of subjects: 407
Study: 24641778

Group type: EXPERIMENTAL
Intervention: evolutionary‐driven cognitive therapy (ED‐CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: cognitive therapy (CT)
Number of subjects: 0
Study: 22196576

Group type: EXPERIMENTAL
Intervention: Self-administered relaxation techniques using a CD and booklet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20453178

Group type: EXPERIMENTAL
Intervention: Nutrition classes and family YMCA membership
Number of subjects: 83

Group type: COMPARATOR
Intervention: Nutrition classes only
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: YMCA attendees
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Nonattendees
Number of subjects: 83
Study: 18029326

Group type: EXPERIMENTAL
Intervention: Zofenopril 30 mg + Hydrochlorothiazide 12.5 mg
Number of subjects: 463

Group type: COMPARATOR
Intervention: Zofenopril alone
Number of subjects: 463
Study: 16356182

Group type: EXPERIMENTAL
Intervention: Activity monitor and tailored web-based advice
Number of subjects: 0
Study: 12374437

Group type: EXPERIMENTAL
Intervention: Messages of social exclusion
Number of subjects: 3

Group type: COMPARATOR
Intervention: Predictions of future nonsocial misfortunes (accidents and injuries)
Number of subjects: 3
Study: 10382332

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18000
Study: 7749165

Group type: EXPERIMENTAL
Intervention: Navoban (tropisetron)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Zofran (ondansetron)
Number of subjects: 231
Study: 2408179

Group type: EXPERIMENTAL
Intervention: Basal-bolus therapy using pen-injectors
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 30
Study: 7332090

Group type: EXPERIMENTAL
Intervention: 50 mg tramadol (Tramal)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.3 mg buprenorphine (Temgesic)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both tramadol and buprenorphine
Number of subjects: 50
Study: 31604481

Group type: EXPERIMENTAL
Intervention: Protein-enriched infant formula
Number of subjects: 90

Group type: COMPARATOR
Intervention: Enteral feeding formula with different protein contents
Number of subjects: 90
Study: 28259617

Group type: EXPERIMENTAL
Intervention: Autologous stem cells (Group A)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard technique (Group B)
Number of subjects: 35
Study: 25134779

Group type: EXPERIMENTAL
Intervention: Cognitive exertion (CE) - school curricular lesson
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Physical exertion (PE) - traditional physical education lesson
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Mixed cognitive and physical exertion (CPE) - coordinative physical education lesson
Number of subjects: 116
Study: 23625384

Group type: EXPERIMENTAL
Intervention: Multimedia WiLLOW intervention
Number of subjects: 168
Study: 20935591

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 24046

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 24046
Study: 19436939

Group type: EXPERIMENTAL
Intervention: Clodronate (800 mg daily)
Number of subjects: 5212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5212
Study: 16924565

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 microg four times a day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg two times a day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 10
Study: 15121490

Group type: EXPERIMENTAL
Intervention: Vitamin K-depleted diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vitamin K-enriched diet
Number of subjects: 12
Study: 11157557

Group type: EXPERIMENTAL
Intervention: Patients with involuntary movements
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 9129851

Group type: EXPERIMENTAL
Intervention: Intravenous enalapril
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no ST-depression)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with long-lasting ST-depression (> 60 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with long-lasting ST-depression
Number of subjects: 60
Study: 8186157

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 20
Study: 3063043

Group type: EXPERIMENTAL
Intervention: Topical antibiotics (gentamicin 160 mg + metronidazole 400 mg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Systemic antibiotics only (gentamicin 80 mg + metronidazole 500 mg intravenously)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Topical antibiotics
Number of subjects: 79
Study: 29340815

Group type: EXPERIMENTAL
Intervention: Submucosal tunneling endoscopic resection (STER)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic enucleation (VATE)
Number of subjects: 58
Study: 26662171

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Emergent retrograde ureteroscopic management
Number of subjects: 107
Study: 24618483

Group type: EXPERIMENTAL
Intervention: Citicoline plus patching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patching alone
Number of subjects: 0
Study: 23434724

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study: 21175435

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17581533

Group type: EXPERIMENTAL
Intervention: Fentanyl (0, 0.0625, 0.125, 0.187, and 0.250 mg/70 kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0, 0.125, 0.5, 2, and 8 mg/70 kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Heroin (0, 3.125, 6.25, 12.5, and 25 mg/70 kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Morphine (0, 6.25, 12.5, 25, and 50 mg/70 kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxycodone (0, 6.25, 12.5, 25, and 50 mg/70 kg)
Number of subjects: 8
Study: 16493216

Group type: EXPERIMENTAL
Intervention: Transurethral electrovapor resection of the prostate (TUVRP)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard transurethral resection of the prostate (TURP)
Number of subjects: 76
Study: 12577135

Group type: EXPERIMENTAL
Intervention: Patients with AAAs
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Patients with popliteal aneurysms
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Men with AAAs
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control subjects (age- and gender-matched)
Number of subjects: 54
Study: 10840174

Group type: EXPERIMENTAL
Intervention: CCK‐4 (50 microg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 9342915

Group type: EXPERIMENTAL
Intervention: Se-enriched yeast (200 micrograms Se/day)
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Low-Se yeast placebo
Number of subjects: 1312
Study: 8458140

Group type: EXPERIMENTAL
Intervention: Active stimulators
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dummy stimulators (Control)
Number of subjects: 40
Study: 3767146

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone, 2 mg/kg body weight
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31895785

Group type: EXPERIMENTAL
Intervention: RFS confirmed
Number of subjects: 967

Group type: COMPARATOR
Intervention: No RFS
Number of subjects: 967
Study: 29845770

Group type: EXPERIMENTAL
Intervention: Plyometric exercise (10 sets of 10 repetitions at 40% of estimated one-repetition maximum leg press)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-exercise control period
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Plyometric exercise
Number of subjects: 14
Study: 27460201

Group type: EXPERIMENTAL
Intervention: Left high-frequency rTMS with quetiapine (n=12)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Right low-frequency rTMS with quetiapine (n=13)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham stimulation with quetiapine (n=13)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall rTMS with quetiapine (all groups)
Number of subjects: 38
Study: 24681270

Group type: EXPERIMENTAL
Intervention: Mixed bacterial lysate OM-85 BV (n=33)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (IIV) without OM-85 BV (n=35)
Number of subjects: 68
Study: 22773391

Group type: EXPERIMENTAL
Intervention: Contemporaneous portal and arterial revascularization (CPAr)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sequential portal and arterial revascularization (SPAr)
Number of subjects: 80
Study: 19834330

Group type: EXPERIMENTAL
Intervention: Sarpogrelate (oral) for 12 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional therapy (Control group)
Number of subjects: 16
Study: 18491099

Group type: EXPERIMENTAL
Intervention: Dual-source computed tomography (DSCT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Coronary Angiography (CAG)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Follow-up after DSCT
Number of subjects: 33
Study: 16117986

Group type: EXPERIMENTAL
Intervention: Cefdinir oral suspension 7 mg/kg q12h for 5 days
Number of subjects: 357
Study: 12218521

Group type: EXPERIMENTAL
Intervention: 10 mg valdecoxib
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: 20 mg valdecoxib
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: 40 mg valdecoxib
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: 80 mg valdecoxib
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study: 10499776

Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 2

Group type: COMPARATOR
Intervention: Asymptomatic HIV-positive patients
Number of subjects: 2
Study: 8941460

Group type: EXPERIMENTAL
Intervention: s-HBOT
Number of subjects: 70
Study: 2011701

Group type: EXPERIMENTAL
Intervention: 1 g sucralfate granulate given four times daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: 400 mg cimetidine twice daily
Number of subjects: 60
Study: 6218781

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 59
Study: 29528175

Group type: EXPERIMENTAL
Intervention: Modified Monolithic Zirconia (MMZ)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metal-Ceramic (MC)
Number of subjects: 40
Study: 27150346

Group type: EXPERIMENTAL
Intervention: Cognitive remediation group (JCORES)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 62
Study: 27151008

Group type: EXPERIMENTAL
Intervention: DICE regimen combined with rituximab
Number of subjects: 90

Group type: COMPARATOR
Intervention: GDP regimen combined with rituximab
Number of subjects: 90
Study: 25128022

Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 139

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 139
Study: 22435877

Group type: EXPERIMENTAL
Intervention: Deferasirox therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active malignancy or neutropenia at enrollment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pulmonary infection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Higher baseline serum concentrations of iron and ferritin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clinical improvement during the first 14 days of study therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Day 30 clinical response
Number of subjects: 20
Study: 19340492

Group type: EXPERIMENTAL
Intervention: EEGo monitor
Number of subjects: 21

Group type: COMPARATOR
Intervention: BIS monitor
Number of subjects: 21
Study: 17324976

Group type: EXPERIMENTAL
Intervention: Fentanyl plus magnesium sulphate (Group FM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl (Group F)
Number of subjects: 50
Study: 15089024

Group type: EXPERIMENTAL
Intervention: STST group (static stretching, isolated progressive hamstring resistance exercise, and icing)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PATS group (progressive agility and trunk stabilization exercises and icing)
Number of subjects: 24
Study: 12032720

Group type: EXPERIMENTAL
Intervention: naproxen ophthalmic solution
Number of subjects: 408

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 408

Group type: COMPARATOR
Intervention: diclofenac
Number of subjects: 408
Study: 9809141

Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 129

Group type: COMPARATOR
Intervention: Coronary stenting during coronary artery bypass graft
Number of subjects: 129
Study: 7651474

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg of elemental zinc daily)
Number of subjects: 937
Study: 2528425

Group type: EXPERIMENTAL
Intervention: Yiqi Yangyin Huoxue prescription
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 68
Study: 1268617

Group type: EXPERIMENTAL
Intervention: Methyldopa (750 or 1000 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term methyldopa treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methyldopa treatment for two to three weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged methyldopa treatment (mean 13.4 months)
Number of subjects: 0
Study: 31368154

Group type: EXPERIMENTAL
Intervention: Restorative yoga (1-hour guided group session followed by 4 weeks of at-home practice)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Restorative yoga (4 weeks of at-home practice)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual stress relief methods (4 weeks)
Number of subjects: 20
Study: 28747208

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA-101) consolidation therapy
Number of subjects: 188

Group type: COMPARATOR
Intervention: No treatment (standard care)
Number of subjects: 188